Technology in the management of type 2 diabetes: Present status and future prospects.
Technology in the management of type 2 diabetes: Present status and future prospects.
复制标题
DOI：
10.1111/dom.14418
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Hovorka R
中科院分区：
文献类型：
--
作者：
Daly A;Hovorka R
2型糖尿病（T2D）的发病率不断增加，是一个重大的健康问题，占全球糖尿病病例的90%。随着疾病的进展，在许多情况下，所导致的胰岛素缺乏和高血糖症需要胰岛素治疗。人们认识到，大量临床需要胰岛素治疗的人及其医疗保健专业人员由于担心低血糖、对治疗方案了解不多或缺乏参与而不愿意加强胰岛素治疗，因此血糖控制不佳而出现并发症的风险更高。在过去的十年中，糖尿病技术的兴起，包括给药顾问，连续葡萄糖监测系统，胰岛素泵和自动胰岛素输送系统，导致了特别是那些需要胰岛素的治疗方法的巨大改进。虽然重点主要是向1型糖尿病人群提供这些治疗，但人们越来越认识到，T2D患者在达到推荐的血糖标准方面面临着类似的挑战，并且也有可能从这些进展中受益。在这篇综述中，我们讨论了目前可用于T2D患者的糖尿病技术和支持其使用的证据，以及未来的前景。我们的结论是，有临床需要将这些技术的使用扩展到T2D人群，以遏制这一群体中次优疾病管理的后果。
The growing incidence of type 2 diabetes (T2D) is a significant health concern, representing 90% of diabetes cases worldwide. As the disease progresses, resultant insulin deficiency and hyperglycaemia necessitates insulin therapy in many cases. It has been recognised that a significant number of people who have a clinical requirement for insulin therapy, alongside their healthcare professionals, are reluctant to intensify treatment with insulin due to fear of hypoglycaemia, poor understanding of treatment regimens or lack of engagement and are therefore at higher risk of developing complications from poor glycaemic control. Over the past decade, the rise of diabetes technologies, including dosing advisors, continuous glucose monitoring systems, insulin pumps and automated insulin delivery systems has led to great improvements in the therapies available particularly to those requiring insulin. Although the focus has largely been on delivering these therapies to the type 1 diabetes population, it is becoming increasingly recognised that people with T2D face similar challenges to achieve recommended glycaemic standards and also have the potential to benefit from these advances. In this review, we discuss diabetes technologies that are currently available for people with T2D and the evidence supporting their use, as well as future prospects. We conclude that there is a clinical need to extend the use of these technologies to the T2D population to curb the consequences of suboptimal disease management in this group.
登录
查看更多内容
引入智能连接的胰岛素笔之后，范围内的时间增加了，错过的注射量很少。
影响因子：
5.4
作者：
Adolfsson P;Hartvig NV;Kaas A;Møller JB;Hellman J
通讯作者：
Hellman J
影响因子：
5.4
作者：
Bailey T;Bode BW;Christiansen MP;Klaff LJ;Alva S
通讯作者：
Alva S
影响因子：
19.6
作者：
Bally, Lia;Gubler, Philipp;Hovorka, Roman
通讯作者：
Hovorka, Roman
影响因子：
2.4
作者：
Ajjan, Ramzi A.;Jackson, Neil;Thomson, Scott A.
通讯作者：
Thomson, Scott A.
影响因子：
5
作者：
Agarwal, Payal;Mukerji, Geetha;Bhatia, R. Sacha
通讯作者：
Bhatia, R. Sacha